Biophytis SA

ALBPS

Company Profile

  • Business description

    Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

  • Contact

    BC 9, Batiment A 4eme etage
    4 pace Jussieu
    Sorbonne University
    Paris75005
    FRA

    T: +33 144272300

    https://www.biophytis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    24

Stocks News & Analysis

stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks

Is this the $80 billion elephant Warren Buffett has been waiting for?

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks

Tesla: Board announces new pay package for CEO Elon Musk

A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,028.80106.801.20%
CAC 407,621.0410.97-0.14%
DAX 4023,846.0788.380.37%
Dow JONES (US)44,161.8711.77-0.03%
FTSE 1009,142.7314.430.16%
HKSE24,902.53169.080.68%
NASDAQ20,966.6586.93-0.41%
Nikkei 22540,549.54258.840.64%
NZX 50 Index12,877.04193.001.52%
S&P 5006,309.2820.66-0.33%
S&P/ASX 2008,770.40106.701.23%
SSE Composite Index3,617.6034.290.96%

Market Movers